Gotowe bibliografie tematyczne / Tumours

Gotowa bibliografia na temat „Tumours”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 29 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Tumours”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Tumours"

1

Khanam, Shafeya, Maliha Rashid, Zebunnessa Parvin, Shahnaz Akter Jahan, Mirza Md Asaduzzaman, Samar Chandra Saha i Nahid Reaz. "Histological Variants of Ovarian Tumour in Bangladeshi Women". Ibrahim Cardiac Medical Journal 5, nr 1-2 (12.04.2017): 40–44. http://dx.doi.org/10.3329/icmj.v5i1-2.53698.

Pełny tekst źródła
Streszczenie:
Objective: Types of ovarian tumour are widely divergent and no age group is immune from ovarian tumour; but certain ages are more vulnerable to develop certain types of tumours. By far, very few studies describing the histological types and subtypes of ovarian tumour in the context of Bangladeshi population have been conducted. The present study was intended to find the histological variants of ovarian tumours in our women. Methods: The present study was carried out in Dhaka Medical College Hospital between July 2001 to June 2002. The total number of patients admitted with a clinical diagnosis of ovarian tumour during the study period was 238, while the total number of gynaecological admissions was 3189. In the present study every alternate patients of ovarian tumour who consented to participate in the study were included as long as 110 cases were met. After admission, history and clinical presentation were recorded and every case was followed till discharge. Provisional diagnosis was made clinically and by ultrasound when 14 cases were excluded for they did not have ovarian tumour at all. The remaining 96 cases were operated and were confirmed by operative and histopathological findings. Results: In the present study proportion of ovarian tumours was 6.52% of all gynecological admissions. The mean age of the patients was found to be 39.5 ± 6.3 years. The peak age incidence of benign ovarian tumors was found to lie between 21-50 years. Malignant ovarian tumors, however was found more commonly after the age of 50 years. After histopathological confirmation of the precise nature of the 96 ovarian tumors, it was found that benign tumour comprised 77% of the cases with malignant tumors occurring in the rest 23%. Among them tumours of epithelial origin formed 70.8% of all ovarian tumors, germ cell tumors 25% and sex-cord stromal tumours made up 4.2%. Among the epithelial tumors, serous tumors were most frequently seen (61.7%), followed by mucinous tumors (35.3%). The percentage of benign serous cystadenomas was 35.5%. The ratio between serous and mucinous cystadenocarcinoma was almost 2:1. Germ cell tumour found in this study was of moderate frequency (25%). Among them 15.6% were mature teratoma (dermoid cyst) followed by 5.2% dysgerminoma. Endodermal sinus tumors were relatively low (3.1%) and there was a case of immature or malignant teratoma. Sex-cord-stromal tumours were of lowest frequency (4.2%) and classified as ovarian fibroma, granulosa-cell tumor and Krukenberg tumour. Conclusion: The study concluded that benign tumour comprised three-quarters of all ovarian tumours with the rest being malignant. Tumours of epithelial origin forms the main bulk, germ cell tumors about one-quarter and sex-cord stromal and metastatic tumors the least. Among the epithelial tumors, serous tumors were most frequently seen, followed by mucinous tumors. Ibrahim Card Med J 2015; 5 (1&2): 40-44
Style APA, Harvard, Vancouver, ISO itp.
2

M., Fathima Seles, M. Revathy i Madurai Padmanabhan Kanchana. "Steroid cell tumour of the ovary: a case report with review of literature". International Journal of Reproduction, Contraception, Obstetrics and Gynecology 7, nr 8 (26.07.2018): 3425. http://dx.doi.org/10.18203/2320-1770.ijrcog20183362.

Pełny tekst źródła
Streszczenie:
Virilising ovarian tumours account for less than 5% of all ovarian tumours. A steroid cell tumour (SCTs) of the ovary comes under the sex cord stromal tumours and accounts for only 0.1% of all ovarian tumours. Almost 75% are functioning tumors with production of androgenic hormones causing virilisation and cushingoid features. They are usually unilateral, benign with only 25-45% malignant cases. Here authors report the incidence of steroid cell tumour in our institution and discuss about a 37-year-old woman with steroid cell tumour, not otherwise specified who presented with oligomenorrhea followed by amenorrhea, secondary infertility and signs of virilisation.
Style APA, Harvard, Vancouver, ISO itp.
3

Patel, Nirali, Rupali Bavikar, Yesha Parimalbhai Lad, Madhuri Singh, Arpana Dharwadkar i Vidya Viswanathan. "A comparison of the WHO 2004 and WHO 2017 thyroid tumor classifications". Journal of Cancer Research and Therapeutics 20, nr 1 (6.04.2023): 311–14. http://dx.doi.org/10.4103/jcrt.jcrt_1797_22.

Pełny tekst źródła
Streszczenie:
Introduction: The category of borderline malignancy or unknown malignant potential was added to the WHO’s 2017 classification of thyroid tumours. A new histological variety of papillary tumours and Hurthle cell tumours was given as a separate entity. The classification has also adopted the Turin criteria for histological diagnosis of poorly differentiated cancer (PDC). Settings and Design: Descriptive study Methods and Material: From July 2018 to June 2022, 200 thyroid neoplasm patients at a tertiary care facility in western Maharashtra were participated in the prospective research over a period of 4 years. Statistical Analysis Used: The descriptive statistics were used to analyse the collected data. Aim: This study was undertaken to compare the old (2004) and new (2016) WHO classifications and their importance in the treatment of thyroid malignancies. Results: Out of 200 cases, the age range of 31 to 40 years had the greatest number of cases. The ratio of females to males was 5:1. In our study, according to the WHO 2004 classification, malignant tumours comprised 57.5% of the cases, while benign tumours 42.5% of the cases. When tumours were subcategorized, the most frequent benign tumour was follicular adenoma (43.5%) and malignant tumour was papillary thyroid carcinoma (37%). Malignant tumours made up 47.5% of the cases when the tumours were reclassified using the revised WHO 2017 classification, followed by borderline tumours with 27.5% of the cases and benign tumours with 25% of the cases. The most frequent borderline tumour was NIFTP (Noninvasive follicular thyroid neoplasm with papillary-like nuclear features) (17.5%), the most prevalent malignant tumour was papillary carcinoma (including its variant) (32%), and the most frequent benign tumour was follicular adenoma (27%). Conclusion: We concluded that the inclusion of the Boderline Category in the new WHO classification significantly improved thyroid cancer management. WHO 2017 classification prevents under diagnosis (in the case of benign tumors) and over diagnosis (in the case of malignant tumors).
Style APA, Harvard, Vancouver, ISO itp.
4

Shanmugasamy, K., Sneha Mahendran i S. Sowmya. "Extradigital glomus tumour of the forearm- A rare site for an unusual tumour". IP Journal of Diagnostic Pathology and Oncology 7, nr 1 (15.02.2022): 48–50. http://dx.doi.org/10.18231/j.jdpo.2022.010.

Pełny tekst źródła
Streszczenie:
Soft tissue tumors are known to occur by varied presentations with atypical features, especially with regard to vascular tumors. The glomus tumour is an unusual benign neoplasm arising from smooth muscles of the perivascular glomus bodies. While it is known to occur in the extremities, this tumour has a predilection for the sub-ungal region of fingers. Vascular tumors as such, especially glomus tumors presenting in extra digital sites are extremely rare. In literature only five cases are available on extra digital sites and few cases have been reported to involve the gastrointestinal tract, airways, shoulders, wrist, knees and elbows. This report discusses the clinical and histopathological features of an glomus tumour of the forearm with atypical presentation. Glomus tumours should be considered as a differential in any nodule occurring in the extradigital locations. Extradigital tumours need not present as a painful purplish nodule and can be asymptomatic. Surgeons and pathologists have to be aware about the varied presentation of these tumours so that misdiagnosis can be avoided and patient can undergo quicker diagnosis and treatment.
Style APA, Harvard, Vancouver, ISO itp.
5

Munawar Ali Baloch, Ikramuddin Ujjan i Mehnaz Munawar. "Demography and Histopathological presentations of oral and maxillo-facial region tumours in Jamshoro, Pakistan." JMMC 9, nr 2 (18.07.2019): 81–84. http://dx.doi.org/10.62118/jmmc.v9i2.89.

Pełny tekst źródła
Streszczenie:
Introduction: Oral and Pharyngeal cancers are the sixth most common cancer globally. In developing countries, the annual incidence of oral cancer is around 275,000 cases while 130,300 cases of pharyngeal cancers excluding naso-pharynx. Salivary glands tumors are rare accounting for less than 5 % of tumors of head and neck region. The annual incidence of these tumors is 0.05 to 2 cases per 100,000 populations. Majority (over two third quarters) of salivary gland tumors occurs in the parotid glands of which most of them (2/3rd) of them are benign in nature. While most common parotid gland’s benign tumor is Pleomorphic Adenoma. Objective: To assess the morphology and histopathological features of oral and maxillo-facial region tumours among the patients in Liaquat University Hospital, Jamshoro, Sindh. Methodology: A Cross-sectional study was conducted at Liaquat University Hospital, Jamshoro. Data was collected regarding socio-demographic features, anatomical location of tumours and relevant history of patients admitted at surgical, medical and ENT units of Liaquat University Hospital, Jamshoro from January 2016 to January 2018. Histopathological diagnostic record was collected from Research and Diagnostic Laboratory of Liaquat University Hospital, Jamshoro. Results: A total of 160 biopsies were collected from surgical, medical and ENT units of Liaquat University Hospital with maximum (43%) of biopsies were from ENT unit. Most (51%) tumours were benign and 37% were malignant in nature. These tumours of oral and maxillo-facial region were mostly (38%) located in parotid region. Histopathological findings of this study revealed that majority (51%) tumours were Pleomorphic adenoma while (20%) of malignant tumours were Mucoepidermoid Carcinoma. Conclusion: Based on findings of the study, we conclude that the most common anatomical location of oral and faciomaxillary tumours, in either gender, is parotid region. The majority of oral and faciomaxillary tumours were benign; frequently occurring benign tumour was pleomorphic adenoma while most frequent malignant tumour was Muco-epidermoid Carcinoma. Key Words: Faciomaxillary tumours, Salivary glands, Pleomorphic adenoma.
Style APA, Harvard, Vancouver, ISO itp.
6

Shrivastava, Vaidik, Ashwini Tangde, Anil Joshi i Rajan Bindu. "Clinicopathological study of skin tumours". International Journal of Research in Medical Sciences 7, nr 5 (26.04.2019): 1712. http://dx.doi.org/10.18203/2320-6012.ijrms20191664.

Pełny tekst źródła
Streszczenie:
Background: Skin cancers are relatively uncommon malignancies worldwide, but the incidence of skin cancers has progressively increased over the last few decades. The distinction between benign and malignant neoplasm are more difficult to define when they appear in skin than when found elsewhere and histopathological examination is frequently required to establish a definitive diagnosis. Diagnosis of any skin tumours can be done by correlating clinical features and histological features. The aim and objective were to study age-sex wise distribution, clinical presentation and histopathological spectrum of various skin tumours.Methods: This is a retrospective study of three years conducted in the Department of Pathology, Government Medical College, Aurangabad, India from December 2015 to December 2018. Specimens received from Department of Dermatology were fixed in formalin and after adequately processing the sections were stained routinely with H and E stain and properly evaluated for histopathological examination. This study includes tumors of epidermis along with melanogenic tumors and skin appendageal tumors. The data collected was tabulated, analysed and compared to other similar studies.Results: The study consists of 130 cases. The ratio of male to female was 1.24:1. Head and neck region (48.46%) was the most common site observed where skin lesions were present followed by extremities (37.69%). Most of the malignant tumours were presented with non-healing ulcers (30.76%) and Noduloulcerative lesions (20.33%). Out of 130 cases, 83 (63.84%) were benign whereas 47 (36.15%) were malignant tumour. According to WHO classification, keratinocytic tumour 55 (42.30%) was the most common tumour type in the present study. Skin adnexal tumours and melanocytic tumours were observed in 54 (41.53%) and 21 (16.15%) respectively.Conclusions: The skin is a complex organ. Because of complexity of skin, a wide range of diseases can develop from the skin. The majority of benign neoplasms are from skin adnexal group whereas most common malignant neoplasm were from keratinocytic group. Skin adnexal tumors can occur anywhere in the body, however head and neck region constitute the most common site. Skin adnexal tumours are clinically often misdiagnosed, so histopathological examination remains gold standard for their correct diagnosis and for their differentiation between benign and malignant neoplasm.
Style APA, Harvard, Vancouver, ISO itp.
7

Begum, Shahnaz, Ferdousi Begum, Nasimul Gani, Farhana Rahman i Farhana Israt Jahan. "Relationship of Age and Different Histological Types of Ovarian Tumors". Bangladesh Journal of Obstetrics & Gynaecology 32, nr 2 (19.07.2020): 99–105. http://dx.doi.org/10.3329/bjog.v32i2.48281.

Pełny tekst źródła
Streszczenie:
Background: Ovarian tumours are common problem in gynaecology and have varied age of appearance of different histopathological types. Objective: This study was undertaken to find out the relationship of age and different histological types of ovarian tumors Methods: A retrospective study was carried out in the Department of Obstetrics and Gynaecology and Department of Pathology, Sir Salimullah Medical College and Mitford Hospital, Dhaka, during May 2010 and December 2014. Five hundred forty seven (547) cases of ovarian tumours were studied in respect to their age and histopathological appearance. Results: The range of age of patients with ovarian tumour was 11 – 82 years. About 63% malignant and 73% benign ovarian tumours were found in the age group of 20 – 49 yrs. About 31% malignant ovarian tumours and 15% Benign tumours occurred in menopausal woman (≤50 yrs.). Overall, mean age of presentation of ovarian tumours was 34.29± 12.84 yrs. Mean age of patients with malignant ovarian tumour was 40.29± 14.28 (median 40 yrs; mode 45 yrs.). Mean age of benign ovarian tumour was 34.69 ± 13.08 (median 34 yrs; mode 40yrs) and mean age for borderline tumours 32.75 ± 11.70 mm (median 33 yrs., mode 20 yrs.). Mean age of non tumour ovarian masses / cysts was 31.14± 10.76 yrs (median 29.5; mode 25.4). The difference of mean age of occurance of malignant and benign ovarian tumours were statistically significant P<0.00>. Dysgerminoma (mean age 23.5± 4.43) and yolk sac tumour (mean age 18 .00 ± 5.00 yrs) occurred in younger patients. Serous cyst adenocarcinoma, endometriod carcinoma and poorly differentiated carcinoma occurred around 45 years of age. Mean age of presentation of most of the benign ovarian tumours was between 30 – 37 yrs.; except thecoma which occurred in extremes of age. Conclusion: Most of the patients with malignant and benign ovarian tumours have presented in reproductive age adult women (20 – 49 yrs.); and some specific varieties of tumour (e.g. thecoma) presented in the extremes of age. Bangladesh J Obstet Gynaecol, 2017; Vol. 32(2) : 99-105
Style APA, Harvard, Vancouver, ISO itp.
8

Singh, Rohit Kumar, Satyendra K. Tiwary i Puneet . "Gastrointestinal Stromal Tumor: Review". Galore International Journal of Health Sciences and Research 7, nr 1 (29.01.2022): 7–18. http://dx.doi.org/10.52403/gijhsr.20220102.

Pełny tekst źródła
Streszczenie:
Gastrointestinal stromal tumours (GISTs) are one of the most common mesenchymal tumors affecting the gastrointestinal (GI) tract. GIST has undergone outstanding development in how they are presented, classified, assessed, diagnosed and treated over the last decade. Gastrointestinal stromal tumours (GIST) account for nearly less than 3% of all malignant GI tumours. The clinical presentation can differ depending on its location, tumour size and aggressiveness of the tumour. In this comprehensive review, we talk regarding the epidemiology, clinical features and diagnostic modalities for GIST. We also discuss our view regarding the treatment options for early stage, locally advanced and metastatic GIST. Indications for neoadjuvant and adjuvant therapy along with time of therapy are also explained. A concise discussion of most recent biomarkers is also provided. Keywords: GIST, Leiomyoma, Leiomyosarcoma, Leiomyoblastoma, Stromal tumours, Mesenchymal neoplasm.
Style APA, Harvard, Vancouver, ISO itp.
9

Petrányi, Ágota, i György Bodoky. "Drugs for the treatment of neuroendocrine tumours". Orvosi Hetilap 152, nr 10 (marzec 2011): 379–91. http://dx.doi.org/10.1556/oh.2011.29060.

Pełny tekst źródła
Streszczenie:
Neuroendocrine tumours are heterogeneous and rare malignancies arising from endocrine cells located in various anatomical locations. Neuroendocrine tumours can be functional and may produce a wide variety of mediators, however, the majority of neuroendocrine tumours do not produce biologically active hormones (non-functioning tumours). On the basis of their pathological and biological characteristics they can be well differentiated as low malignant and poorly differentiated highly malignant tumours. In the case of the advanced low malignant tumours the application of somatostatin analogues not only may control symptoms but they also have direct anti-tumour effect. The use of higher doses of somatostatin analogues or new subtype selective agonists, and chimeric or pan-somatostatin analogues will probably improve the clinical management of the patients who fail to respond to standard somatostatin analogue treatment. Data show that somatostatin analogues and interferon have a synergistic effect. The currently used chemotherapy in progressive neuroendocrine tumors is mainly devoted to poorly differentiated tumours, but also to well differentiated carcinomas which are either not eligible or resistant to other therapies. However, the new anti-tumoural agents, could eventually replace these old recipes in the near future. Clinical trials show that telozomide with capecitabine result in more favorable toxic profile and higher and longer response rate in the case of well-differentiated tumours. Targeted therapy became a new possibility in neuroendocrine tumours too. The monoclonal antibody bevacizumab, which affects the vascular endothelial growth factor receptors, has beneficial effects both in monotherapies and in combination with somatostatin analogues or with oxaliplatine and capecitabine. Recently, the low molecular multikinase inhibitor, sunitinib has demonstrated efficacy in pancreas neuroendocrine tumors, which was proven in a phase 3 trial. The mammalian target of the rapamycin inhibitor everolimus, currently investigated in phase 3 trials, was also efficient in the same subtype. Further trials are needed to determine that in the case of other types of neuroendocrine tumours which targeted therapy could be efficient. Radioisotope-labeled peptide receptor therapy with 131I-MIBG, 90Y-DOTA-TOC or 177Lu-DOTA-TOC may offer a highly effective option for patients with progressive and advanced stage of neuroendocrine tumours. The purpose of this review is to review and analyze data available regarding contemporary chemotherapeutic management of neuroendocrine tumours in order to determine which therapy should be applied in the therapeutic arsenal. Orv. Hetil., 2011, 152, 379–391.
Style APA, Harvard, Vancouver, ISO itp.
10

Alnaami, Ibrahim, Ping Ho, Jian-Qiang Lu i Blaise Wheatley. "Case Report: Meningioma with Intra-tumoural Haemorrhage Secondary to Ruptured Distal Anterior Cerebral Artery Aneurysm". Open Neuroimaging Journal 7, nr 1 (18.10.2013): 32–34. http://dx.doi.org/10.2174/1874440001307010032.

Pełny tekst źródła
Streszczenie:
Background: Brain tumours that are associated with cerebral aneurysms are rare occurrences, whereas the coexistence of brain tumours and intra-tumoural aneurysms is even rarer. There have been 12 brain tumour cases that have been reported in the literature that describe an aneurysm within a brain tumour, with 4 of these tumours being meningiomas. Case description: A 34-year-old male patient presented with sudden-onset headache, and an inter-hemispheric meningioma with intra-tumoural bleeding was found due to a ruptured embedded anterior cerebral artery aneurysm. The aneurysm was diagnosed incidentally on the third cerebral angiogram, while the initial 2 angiograms were negative. The patient was treated with endovascular aneurysm embolisation that was followed by tumour resection. Conclusion: This paper is the first case report to describe the coexistence of a meningioma and an aneurysm, which presented with intra-tumoural haemorrhage that was negative on the initial cerebral angiogram. Unlike previous case reports, the aneurysm in this case was located with an anterior cerebral artery distribution.
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Tumours"

1

Kamel, H. M. N. "Ultrastructural aspects of tumours and anti-tumour therapy". Thesis, University of Glasgow, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.375440.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Khan, M. S. "Circulating tumour cells and biomarkers in neuroendocrine tumours". Thesis, University College London (University of London), 2013. http://discovery.ucl.ac.uk/1380186/.

Pełny tekst źródła
Streszczenie:
Neuroendocrine tumours(NETs) are heterogeneous with respect to biological behavior. Consequently, prognosis is variable and biomarkers predicting survival or tumour progression are required to inform clinical management. The best available biomarker, histological grade, is assigned using Ki-67 or mitotic count. Agreement between these two indices is implied but analysis of 131 pancreatic and 136 midgut NETs suggested discordances of 44% and 38% respectively. Ki-67 was the superior prognostic marker, making the additional value of mitotic count questionable. Detection of Circulating Tumour Cells(CTCs) using the Cellsearch™ platform requires expression of epithelial cell adhesion molecule(EpCAM). I demonstrated EpCAM expression by immunohistochemistry and detected CTCs in patients with metastatic NETs. In 175 patients, ≥1 CTC was detected in 51%(midgut) and 36%(pancreatic). ≥1 CTC was an independent poor prognostic factor, offering better prognostic value than grade or chromogranin A(CgA). Changes in CTCs 3-5 weeks after commencing therapy were predictive of response and survival, suggesting CTCs could provide an early assessment. Using chip-based capillary-electrophoresis, higher concentrations of circulating free DNA(cfDNA) were found in 88 patients with NETs compared to healthy controls with a correlation between cfDNA quantity and CTCs. Since cfDNA was detected in 25% of cases, more sensitive methods of detection are required before studies are conducted to validate cfDNA as a biomarker and to analyse mutations. The hypervascular nature of NETs suggested that circulating endothelial cells(CECs) might be informative. Using immunomagnetic separation and CD105 phenotyping, CECs were demonstrated in 55 patients. Although not significantly elevated, there was a wider range of CECs in NETs compared to controls. Further studies investigating changes with anti-angiogenic therapy could prove valuable. My research suggests circulating biomarkers, specifically CTCs, provide additional and better prognostic information than grade. Furthermore, detection of CTCs and cfDNA in NETs may allow future studies into molecular analysis, which may enhance understanding of NET pathogenesis.
Style APA, Harvard, Vancouver, ISO itp.
3

de, Foy K. "Analysis of candidate tumour suppressor genes in sporadic ovarian tumours". Thesis, University of Cambridge, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.598448.

Pełny tekst źródła
Streszczenie:
The aim of this thesis was to identify genes which are important in the initiation and/or progression of sporadic ovarian cancer. A series of ovarian teratomas and carcinomas was collected and three candidate tumour suppressor genes were analysed. The c-mos gene is an ovarian teratoma susceptibility gene in mice; its absence causes the growth of these tumours. Twenty human ovarian teratomas were collected and the coding region of the c-mos gene was analysed for somatic and germline mutations. No disease-causing alterations were found. Germline mutations of the BRCA2 gene predispose individuals to breast and ovarian cancer. To determine whether mutations in BRCA2 are important in sporadic ovarian cancer, loss of heterozygosity studies and mutation analysis were carried out on BRCA2 in a series of sporadic epithelial ovarian tumours. Loss of heterozygosity was identified in 46% of tumours. Four truncating mutations were identified in 50 tumours, two of which were germline and two somatic. All four mutations were accompanied by loss of the second allele. These results suggest that BRCA2 behaves as a tumour suppressor gene but that somatic mutations are not a common even in sporadic ovarian cancer. The insulin-like growth factor II receptor gene (IGF2R) on chromosome 6q is in a region which is frequently lost in ovarian tumours. A loss of heterozygosity analysis of the IGF2R locus in 38 informative epithelial ovarian tumours demonstrated 55% with loss of one allele. To perform mutation analysis of IGF2R, the technique of fluorescent chemical cleavage of mismatch was established in the laboratory and used to analyse IGF2R cDNA from 18 tumours. No disease-causing alterations were identified. Antibodies were used to examine the expression of the IGF2R protein through immunohistochemical studies of 53 ovarian tumour tissue sections. Seven tumours were identified in which epithelial tumour cells stained negatively for IGF2R. No correlation could be found between immunohistochemical results and LOH and mutation analysis results, suggesting that IGF2R is probably down-regulated at the level of transcription or translation in those samples which showed negative staining.
Style APA, Harvard, Vancouver, ISO itp.
4

Orme, Michelle Elaine. "The vascularization of solid tumours : mathematical models of tumour angiogenesis and vascular tumour growth". Thesis, University of Bath, 1996. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.362238.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Liu, Lu. "Oncogenes and tumour suppressor genes in human central nervous system tumours /". Stockholm, 1999. http://diss.kib.ki.se/1999/91-628-3532-7/.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Gillmore, Roopinder. "Studies of the Wilms' tumour 1 gene in patients with solid tumours". Thesis, Imperial College London, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.432012.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Byrne, Niall Maurice. "Importance of the tumour microenvironment in the treatment response of prostate tumours". Thesis, Ulster University, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.674729.

Pełny tekst źródła
Streszczenie:
Androgen deprivation therapy (ADT) such as bicalutamide (BCA) has become the mainstay of treatment for locally-advanced prostate cancer (PCa). Despite initial remissions, ADT resistance almost inevitably occurs with progression to metastatic castrate-resistant PCa. Hypoxia is a common hallmark of many solid tumours and is associated with treatment failure and malignant progression; androgen withdrawal has been shown to induce profound hypoxia in androgen-sensitive tissue. This prompted an investigation into the effect of ADT on tumour oxygenation and malignant progression in PCa. Androgen-dependent luciferase-expressing PCa xenografts (LNCaP-luc) were implanted in SCID mice. When tumours reached -150mm3 mice were treated daily with SCA (2 or 6mg/kg). A reduction in tumour oxygen was observed within 24hrs (Oxylite™ oxygenelectrode); this continued to a nadir of 0.1 % oxygen at day 3 or 7 respectively. Tumours remained profoundly hypoxic until day 14-21 when oxygen levels began to rise, concomitant to time-dependent remodelling of the tumour vasculature (dorsal skin fold model). By day 28, BCA-treated xenografts were more malignant and showed greater metastatic spread to the lungs. Gene expression changes during BCA treatment of LNCaP xenografts were investigated using qPCR arrays; significant differences were found in the expression many genes involved in angiogenesis, invasion and metastasis, apoptosis resistance and the PI3K1AktimTOR signalling pathway. Informed treatment regimens combining SCA with a unidirectional hypoxia activated prod rug (AQ4N and its novel analogue OCT1002; 50mg/kg, day 7) or an Akt inhibitor (30mg/kg t.i.w) resulted in a reduction in tumour growth and metastatic spread to the lungs. When the anti-angiogenic VEGF-inhibitor (B20.4.1.1; 5mg/kg, day 14) was combined with bicalutamide, this blocked the revascularisation associated with BCA alone. This study shows that BCA-induced hypoxia induces critical changes in the tumour microenvironment which cause modified gene expression and drives malignant progression. Targeted therapeutic regimens, informed by this knowledge, may improve treatment outcomes of androgen-dependent PCa.
Style APA, Harvard, Vancouver, ISO itp.
8

Euler, Henrik von. "Electrochemical treatment of tumours /". Uppsala : Dept. of Small Animal Clinical Sciences, Swedish Univ. of Agricultural Sciences ([Institutionen för kirurgi och medicin - smådjur], Sveriges lantbruksuniv.), 2002. http://epsilon.slu.se/v133.pdf.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Dwivedi, Anupma. "Bacteriolytic therapy of tumours". Thesis, University of Ulster, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.589756.

Pełny tekst źródła
Streszczenie:
The historical precedence for employing bacteria to target cancer stretches long back some 300 years. Despite of the advancements in chemotherapy, problems such as metastasis and tumour resistance to chemotherapy and radiotherapy have limited the scope of therapeutic effects of existing clinical treatments. The microenvironment of solid tumours provides an ideal environment for growth of facultative and strictly anaerobic bacteria. These bacteria can colonize such environments leading to tumour regression. Such investigations have given the concept of bacteriolytic therapy, in which live bacteria could be employed for the targeted delivery into tumours leading to its suppression. With this concept in mind it was decided to explore the above idea by using probiotic bacterium (Lactobacillus casei), which is considered to be non-pathogenic and also provides health benefits to the host. In order to minimize dispersion of the bacteria throughout the host and to facilitate its delivery into tumours, some kind of containment was desirable. To test this kind of approach it was decided to exploit immobilisation technology to microencapsulate live bacteria for later injection into tumour sites. To date no such approach has been employed to develop such a microencapsulation system that could be utilized as a delivery vehicle for live bacteria to deliver it through a hypodermic needle directly into tumours. In order to pursue the above objective, the microencapsulation method was also characterised with respect to stability and viability of the L.casei. Microencapsulated preparations of Lactobacillus casei NCDO 161 were developed and demonstrated that the culture supernatant of microencapsulated preparation inhibited growth of tumour cells (in vitro). Further investigation of a variety of bacterial preparations on tumour growth (in vivo) following intra-tumoural injection demonstrated that the live microencapsulated preparation had severe inhibitory effect on tumour growth when compared with non-encapsulated live and encapsulated heat killed preparations. Histological studies were performed to demonstrate the presence of live bacteria in tumours at early stages and to study the effects of the bacteria on tumour architecture during the treatment.
Style APA, Harvard, Vancouver, ISO itp.
10

Burns, Alice Sin Ying Wai. "The role of the p53 tumour suppressor pathway in central primitive neuroectodermal tumours". Thesis, University of Newcastle Upon Tyne, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.300357.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Tumours"

1

Oosterhuis, Jendo A., red. Ophthalmic Tumours. Dordrecht: Springer Netherlands, 1985. http://dx.doi.org/10.1007/978-94-009-5520-2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Yalcin, Suayib, i Kjell Öberg, red. Neuroendocrine Tumours. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-45215-8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Puri, Prem, red. Neonatal Tumours. London: Springer London, 1996. http://dx.doi.org/10.1007/978-1-4471-3028-4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

A, Fagin James, red. Pituitary tumours. London: Baillière Tindall, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

J, Johnson P., red. Liver tumours. London: Baillière Tindall, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

1931-, Williams Roger, i Johnson P. J, red. Liver tumours. London: Baillière, 1987.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Prem, Puri, i Surana Rajendra FRCSI, red. Neonatal tumours. London: Springer, 1996.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

M, Polak Julia, i Bloom Stephen Robert, red. Endocrine tumours: The pathobiology ofregulatory peptide-producing tumours. Edinburgh: Churchill Livingstone, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Peter, Chambers, i BACUP, red. Understanding brain tumours. London: BACUP, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Thomas, David G. T., i David I. Graham, red. Malignant Brain Tumours. London: Springer London, 1995. http://dx.doi.org/10.1007/978-1-4471-1877-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Tumours"

1

Assadi, Majid, Reza Nemati, Hossein Shooli i Hojjat Ahmadzadehfar. "Radionuclide Therapy in Brain Tumours". W Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum, 109–25. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_10.

Pełny tekst źródła
Streszczenie:
AbstractGlioblastoma multiforme (GBM), the most common primary brain tumour, is also the most aggressive neoplasm in the brain. It is characterized by a very poor prognosis with a median overall survival time of only 9–15 months. The infiltrating nature of the tumour cells, inter- and intra-tumoral molecular heterogeneity and the tumour’s propensity to hide behind the blood-brain barrier are the key causes of the insufficiency of the optimal available treatments (surgery, radiotherapy and chemotherapy). Furthermore, the best treatment strategy for patients with recurrent GBM remains uncertain and controversial yet. Despite applying state-of-the-art treatments in the majority of patients, the recurrence of the disease is common and the median survival after recurrence is 8.0–9.8 months. In order to avoid treatment insufficiencies, precision medicine-based therapeutics have emerged. An alternative method of treatment is targeted radionuclide therapy, which targets tumour-specified molecules on the surface of tumour cells. It has been shown that brain tumours overexpress several peptides on their surface, which may or may not be immunologically active, that can be used as a biologic target for the therapy. Radionuclide therapy involves the coupling of a peptide, which targets tumour-specific peptides, with a radionuclide payload to selectively irradiate tumour cells with negligible damage to the adjacent healthy tissue. This chapter discusses the use of radiolabelled conjugates for the treatment of brain tumours.
Style APA, Harvard, Vancouver, ISO itp.
2

Valk, Jaap. "Intracranial Tumours (Cerebral Tumours)". W MRI of the Brain, Head, Neck and Spine, 65–125. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3351-4_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Barua, Ranadhir. "Tumours". W Tumours of the Female Lower Genital Tract, 289–385. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74828-8_23.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Gordon, Isky, Klaus Hahn i Sibylle Fischer. "Tumours". W Atlas of Bone Scintigraphy in the Pathological Paediatric Skeleton, 91–182. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-61060-8_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Rana, Abdul Qayyum, Lawrence A. Zumo i Valerie Sim. "Tumours". W Neuroradiology in Clinical Practice, 39–49. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01002-1_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Warwick, David, Ashley Blom, Michael Whitehouse i Richard Gardner. "Tumours". W Apley & Solomon's Concise System of Orthopaedics and Trauma, 161–97. Wyd. 5. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9780429243974-10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Ritchie, D. A., A. M. Davies i D. Vanel. "Tumours and Tumour-like Lesions". W Imaging of the Foot & Ankle, 325–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-59363-5_20.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Chomette, G., i J. Diebold. "Tumours and Tumour-like Lesions". W Diseases of the Arterial Wall, 651–79. London: Springer London, 1989. http://dx.doi.org/10.1007/978-1-4471-1464-2_37.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Davies, A. Mark, i Daniel Vanel. "Tumours and Tumour-like Lesions". W Imaging of the Knee, 307–35. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55912-9_18.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Pedrazzoli, Paolo, i John B. A. G. Haanen. "Developments in Solid Tumours". W The EBMT/EHA CAR-T Cell Handbook, 105–8. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_19.

Pełny tekst źródła
Streszczenie:
AbstractChimeric antigen receptor (CAR) T cells have emerged as breakthrough therapies in patients with refractory haematologic malignancies, and the highly encouraging clinical results have fuelled expectations of implementing these strategies in other cancer types. However, a similar success of CAR-T cell treatment has not yet been observed in solid tumours. Various factors, including the immunosuppressive nature of the tumour microenvironment, hinder CAR-T cell trafficking and infiltration into scarcely accessible tumour sites, and difficulties in identifying targetable antigens with optimal expression and a good toxicity profile, limiting CAR-T dose escalation, must be overcome to achieve success in the treatment of solid cancers (Comoli et al. 2019).
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Tumours"

1

Iqbal, S. A., H. Shukla, V. Jain, S. Giri, R. Sekhon i S. Rawal. "Synchronous primary ovarian sex cord tumor and endometrial cancer". W 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685384.

Pełny tekst źródła
Streszczenie:
Synchronous primary tumors of female genital tract are rare with a rate of about 0.7-1.8% of all gynaecological tumours. Most common primary tumours presenting as synchronous lesions are ovary and endometrium. However, sex cord stromal tumors are rare variety of primary ovarian tumor and synchronous with endometrium is even much rarer. These tumors are detected usually in younger, overweight, nulliparous and perimenopausal female. Synchronous primary tumors of endometrium and ovary have a better prognosis than the either of above alone because these are usually low grade and diagnosed at early stage. We present a report of four cases of synchronous endometrial and sex cord stromal tumors of ovary.
Style APA, Harvard, Vancouver, ISO itp.
2

Veena, P. "Single centre experience of ovarian germ cell tumours over 8 years". W 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685316.

Pełny tekst źródła
Streszczenie:
Introduction: Germ cell tumours comprise approximately 15-20% of all ovarian tumours. Two third of ovarian tumours in first two decades of life are germ cell tumours. Majority of ovarian germ cell tumours are benign teratomas. The malignant germ cell tumours are usually solid and arise from totipotent germ cells. Over the past 3 decades the clinical outcome of women with ovarian germ cell tumours (OGCT) have significantly improved mainly due to development of more effective chemotherapy regimens. Objective: To study the clinic pathological features, treatment and survival of women with ovarian germ cell tumours. Methods: This is a retrospective descriptive study taken from the case files of patients with histo-pathologically proven ovarian germ cell tumours who were treated in JIPMER over 8 years from 2007 to 2014. Results: There were totally 63 patients with ovarian germ cell tumours over 8 years who were treated in JIPMER. The age at presentation varies from 12 years to 65 years with a median age of 26.5 years. Three were pre pubertal and 1 was post-menopausal. Twenty two women (34%) were unmarried and 5 were pregnant at the time of presentation. Forty eight (76%) of them did not have any menstrual abnormalities. Pain abdomen (55%) was the most common presentation. Ten of them presented with acute abdomen of which 8 were torsion, 1 was ruptured dermoid and 1 was infected dermoid. Another 6 patients had torsion which was diagnosed only during surgery. Majority (68%) were benign tumours (dermoid) and among malignant tumours, there were 6 dysgerminomas, 5 immature teratomas, 5 mixed germ cell tumours and 4 yolk sac tumours. Almost half (22 out of 43) of women with benign tumours were <25 years whereas 3/4th (14 out of 20) of women with malignant germ cell tumours were <25 years. The most common tumour marker which was elevated was alpha feto protein (8) followed by LDH (5). Fertility sparing surgery (salpingo-ovariotomy) was commonly performed which was 95% (41/43) in benign tumours and 60% (8/20) in malignant tumours. Contra lateral ovary was biopsied in only 5 patients with suspected involvement (negative on final HPR). Out of 20 women with malignant ovarian tumours 7 were in advanced stage (Stage III). Majority of them recovered well from surgery, only 12% had post-operative febrile morbidity and one patient had subclavian vein thrombosis on post op D9 which required anticoagulants. 7 of 20 women received chemotherapy (BEP) for 4 cycles. No serious side effects of chemotherapy were noted in these women. 3 out of 20 women with malignant germ cell tumour were lost to follow up. No recurrences have been found in rest of the women and there are no deaths till last follow up. Conclusion: Advances in the field of medicine like effective chemotherapy regimens, improved imaging, precise surgical staging and fertility sparing surgical procedures enable women not only to preserve the reproductive function but also to improve their quality of life.
Style APA, Harvard, Vancouver, ISO itp.
3

Satish, Pranav, Alex Freeman, Daniel Kelly, Alex Kirkham, Clement Orczyk, Benjamin Simpson, Francesco Giganti, Hayley Whitaker, Mark Emberton i Joseph Norris. "Prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: A systematic review and meta-analysis". W VIRTUAL ACADEMIC SURGERY CONFERENCE 2021. Cambridge Medicine Journal, 2021. http://dx.doi.org/10.7244/cmj.2021.04.001.2.

Pełny tekst źródła
Streszczenie:
Introduction The implications of tumour location on mpMRI conspicuity are not fully understood. Identifying topographical correlates that influence conspicuity may improve outcomes. Here, we present the first systematic review and meta-analysis describing the effect of tumour location on prostate cancer conspicuity on mpMRI. Methods Medline, PubMed, EMBASE and Cochrane databases were systematically searched and results were assessed as per the PRISMA statement. Differential tumour conspicuity on mpMRI was compared between cancers in the peripheral zone (PZ), transitional zone (TZ), base, apex, anterior and posterior. Meta-analysis was conducted to compare diagnostic odds ratios (DOR) of mpMRI detection for tumours in the PZ and TZ. PROSPERO registration: CRD42021228087. Results Thematic synthesis showed apical and basal tumours had reduced conspicuity compared to mid-gland tumours. Cancer in the TZ demonstrated increased conspicuity on T2-weighted imaging, whilst PZ cancers had higher conspicuity on diffusion-weighted and dynamic contrast enhancement imaging. mpMRI had better diagnostic accuracy for PZ lesions, albeit higher specificity for TZ lesions. Meta-analysis showed an increased DOR for PZ tumours (OR: 7.206 [95% CI: 4.991;10.403], compared to TZ (OR: 5.310 [95% CI: 3.082; 9.151]). However, the test for subgroup differences was not significant (p = 0.2743). Conclusions Cancer in the apex or base of the prostate may be less conspicuous than mid-gland tumours. Similarly, TZ cancer appears to have reduced conspicuity compared to PZ cancer, however, meta-analysis did not show a significant difference between DOR. Future larger studies with prospective datasets are required to clarify the relationship between tumour position and conspicuity.
Style APA, Harvard, Vancouver, ISO itp.
4

Pariyar, Jitendra, i Binuma Shrestha. "Clinical presentation and management of malignant germ cell ovarian tumours in BPKMCH". W 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685406.

Pełny tekst źródła
Streszczenie:
Background: Germ cell malignancies account for about 5% of all ovarian cancers. These tumours grow rapidly and often produce symptoms quicker than the slow growing epithelial tumour. Commonly seen in the first two decades of life germ cell malignancies are highly chemosensitive and are potentially curable with surgery and chemotherapy. This study is the first of its kind regarding the epidemiology, management and outcome of patients with malignant germ cell tumour in Nepal. Objective: To analyze the clinical presentation and management outcomes of malignant germ cell tumours managed in B.P. Koirala Memorial Cancer Hospital, Nepal. Methodology: Descriptive study conducted in B.P. Koirala Memorial Cancer Hospital, Nepal. Case records of malignant germ cell tumours attending the hospital from January 1999 to December 2009 were analyzed regarding their illness history, clinical examination, investigations, treatment, follow-up and outcomes measured. Observations: Total 65 cases of malignant germ cell tumours with age range from 2 to 58 years (mean 21.7 years) were received. 42% cases were Tibeto-Burmese; 30% were Indo-Aryans. There were 15 cases (23%) of dysgeminoma, 21 endodermal sinus tumor (32%), 16 Immature Cystic Teratoma (24.5%), 9 (14%) Mixed Germ Cell, 2 unclassified GCT (3.5%) and 2 malignant transformation in teratoma (3.5%). 33 (49.5%) patients had early stage disease, 37 (57%) underwent fertility preserving surgery. 4 cases (9%) due to disseminated disease, underwent neoadjuvant chemotherapy followed by debulking surgery. 51 cases (78.5%) received adjuvant chemotherapy (BEP or EP regimen). The overall survival was 70%. Conclusion: Early stage germ cell malignancies can be safely managed by fertility preserving surgery followed by, chemotherapy if indicated. For advanced diseases, neoadjuvant chemotherapy followed by surgery can be undertaken with curable intent.
Style APA, Harvard, Vancouver, ISO itp.
5

Razzini, Agustin, i Daiana Goldy. "Skull Base - Tumours And Tumour-Like Lesions". W Radiopaedia 2024 Virtual Conference. Radiopaedia.org, 2024. http://dx.doi.org/10.53347/rposter-2470.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Mukhopadhyay, Asima, Nicola Curtin i Richard Edmondson. "Evaluation of different methods to assess homologous recombination status and sensitivity to PARP inhibitors in ovarian cancer". W 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685289.

Pełny tekst źródła
Streszczenie:
Methods: Matched samples of ascites and tumor tissue were taken from patients undergoing surgery for epithelial ovarian cancer. Tumor samples were formalin fixed and paraffin embedded (FFPE); ascites samples were used to generate primary cultures (PC). HR status was determined in PCs as previously described.[1] IC50 for the PARP inhibitor Rucaparib was estimated using SRB assays. DNA was extracted from the FFPE tissue. The following techniques were evaluated in PCs or paired FFPE samples: DR-GFP reporter assay, PARP activity assay, BRCA1 expression on immunohistochemistry, BRCA1 methylation status and BRCA1/2 mutation analysis. A next generation sequencing based assay was used to detect mutations and other genomic alterations in a large panel of cancer-associated genes, including BRCA1/2. Results: Paired samples were collected from 64 patients and characterized for HR function. 47/64 (76%) were high grade serous. 44% (28/64)) were HR defective (HRD) by Rad51 assay and correlated with Rucaparib sensitivity (PPV-92%, NPV-100%). Molecular analysis revealed that all mutations and other genomic alterations detected in ascites derived PCs were also found in matched FFPE tumor tissues. All tumors with serous histology contained p53 mutations, whilst the remaining tumors without p53 mutations were non-serous in histology. DR-GFP assay was unreliable in PC due to poor transfection. In a subset of 50 cancers there was reduced BRCA1 expression in the HRD vs. HRC tumours (34.8% vs. 22.7%, ns) whilst in a further subset of 30 cases there was no difference in endogenous or stimulated PARP activity between HRD and HRC tumours. Deleterious BRCA2 mutations were identified in 7 tumors, 6 of which were HRD. Only 1 deleterious BRCA1 mutation was detected but methylation of BRCA1 was identified in 13 of 64 (20%) tumors, 7 of which were HRD. Mutation of BRCA2 was mutually exclusive to methylation of BRCA1. HRD vs. HRC tumours showed BRCA1 methylation (25% vs. 17%) and BRCA1/2 mutation (21% vs. 0.3%). 14/28 (50%) HR defective tumors do not have BRCA1/2 mutations or BRCA1 methylation, suggesting other mechanisms can also result in a HR defective phenotype. 28/64 (43%) of samples demonstrated the HR defective phenotype. In all cases HR status correlated with sensitivity to Rucaparib. Conclusion: As expected, deleterious BRCA2 mutations conferred a HRD phenotype in cells but methylation of BRCA1 was not universally associated with HRD. This may be as a result of only partial silencing of the gene by methylation and further work is required to identify thresholds of methylation which may predict HR status. The use of BRCA1/2 mutation testing alone is unlikely to identify the majority of HR defective ovarian tumors. Assessment of functional status of HRD is the preferred option and further technologies should be developed to simplify the Rad51 assay.
Style APA, Harvard, Vancouver, ISO itp.
7

Dassios, George. "On ellipsoidal tumours". W 2008 8th IEEE International Conference on Bioinformatics and BioEngineering (BIBE). IEEE, 2008. http://dx.doi.org/10.1109/bibe.2008.4696651.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Hena, Kausar, Manchanda Rahul, Lekhi Anshika, Chitra C. H. Sravani i Jain Nidhi. "Granulosa cell tumour of ovary in a benign looking adnexal mass: A rare occurrence and its management". W 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685402.

Pełny tekst źródła
Streszczenie:
Granulosa cell tumours are sex cord stromal tumours of the ovary which accounts for 1-2% of all ovarian malignancies. We present a case of a 22 yrs old unmarried girl with chief complaints of dysmenorrhoea for last 4 months. There were no other symptoms and her general physical examination revealed no abnormality. Ultrasonography showed a simple ovarian cyst of 7 x 8 cm in right adnexa with normal Doppler flow and no ascites. Her tumour markers were negative. Per-operative uterus and left sided ovary and upper abdomen was normal. Right ovary showed a simple unilocular cyst of around 8 x 8 cm and right ovarian cystectomy done. Surprisingly histopathological examination of cyst wall revealed granulosa cell tumour. Immunohistochemical staining was found to be positive especially with inhibin. Staging laparoscopy with peritoneal wash, multiple peritoneal biopsy with right sided salpingo-oopherectomy, left sided ovarian biopsy and dilatation and curettage was done. Cytological and histopathlogical examination were found to be normal. Post operatively patient received chemotherapy because cyst wall was ruptured per-operatively and patient is doing fine and disease free till now.
Style APA, Harvard, Vancouver, ISO itp.
9

Singh, Manpreet, Qimei Gu, Ronghui Ma i Liang Zhu. "Temperature Distribution and Thermal Dosage Affected by Nanoparticle Distribution in Tumours During Magnetic Nanoparticle Hyperthermia". W ASME 2019 6th International Conference on Micro/Nanoscale Heat and Mass Transfer. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/mnhmt2019-4233.

Pełny tekst źródła
Streszczenie:
Abstract Recent microCT imaging study has demonstrated that local heating caused a much larger nanoparticle distribution volume in tumors than that in tumors without localized heating, suggesting possible nanoparticle redistribution/migration during heating. In this study, a theoretical simulation is performed to evaluate to what extent the nanoparticle redistribution affects the temperature elevations and thermal dosage required to cause permanent thermal damage to PC3 tumors. Two tumor groups with similar sizes are selected. The control group consists of five PC3 tumors with nanoparticles distribution without heating, while the experimental group consists of another five resected PC3 tumors with nanoparticles distribution obtained after 25 minutes of local heating. Each generated tumor model is attached to a mouse body model by microCT scans. A previously determined relationship between the nanoparticle concentration distribution and the volumetric heat generation rate is implemented in the theoretical simulation of temperature elevations during magnetic nanoparticle hyperthermia. Our simulation results show that the average steady state temperature elevation in the tumors of the control group is higher than that in the experimental group when the nanoparticles are more spreading from the tumor center to tumor periphery (control group: 64.03±3.2°C vs. experimental group: 62.04±3.07°C). Further we assess the thermal dosage needed to cause 100% permanent thermal damage (Arrhenius integral Ω = 4) to the entire tumor, based on the assumption of unchanged nanoparticle distribution during heating. The average heating time based on the experimental setting from our previous studies demonstrates significantly different designs. Specifically, the average heating time for the control group is 24.3 minutes. However, the more spreading of nanoparticles to tumor periphery in the experimental group results in a much longer heating time of 38.1 minutes, 57° longer than that in the control group, to induce permanent thermal damage to the entire tumor. The results from this study suggest that the heating time needed when considering dynamic nanoparticle migration during heating is probably between 24 to 38 minutes. In conclusion, the study demonstrates the importance of including dynamic nanoparticle spreading during heating into theoretical simulation of temperature elevations in tumors to determine accurate thermal dosage needed in magnetic nanoparticle hyperthermia design.
Style APA, Harvard, Vancouver, ISO itp.
10

Wang, Lulu, i Hu Peng. "A Feasibility Study of Lung Cancer Detection Using Holographic Microwave Imaging". W ASME 2017 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/imece2017-70062.

Pełny tekst źródła
Streszczenie:
This paper presents the feasibility of using holographic microwave imaging (HMI) method for diagnosing lung tumour. A numerical imaging system is developed to evaluate the working principle, which includes a realistic CT-based thorax model. Results show that various small lung tumours with arbitrary shapes, sizes and locations can be identified in the reconstructed images. The HMI approach has a potential for lung cancer detection.
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Tumours"

1

WANG, MIN, Sheng Chen, Changqing Zhong, Tao Zhang, Yongxing Xu, Hongyuan Guo, Xiaoying Wang, Shuai Zhang, Yan Chen i Lianyong Li. Diagnosis using artificial intelligence based on the endocytoscopic observation of the gastrointestinal tumours: a systematic review and meta-analysis. InPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, luty 2023. http://dx.doi.org/10.37766/inplasy2023.2.0096.

Pełny tekst źródła
Streszczenie:
Review question / Objective: With the development of endoscopic techniques, several diagnostic endoscopy methods are available for the diagnosis of malignant lesions, including magnified pigmented endoscopy and narrow band imaging (NBI).The main goal of endoscopy is to achieve the real-time diagnostic evaluation of the tissue, allowing an accurate assessment comparable to histopathological diagnosis based on structural and cellular heterogeneity to significantly improve the diagnostic rate for cancerous tissues. Endocytoscopy (ECS) is based on ultrahigh magnification endoscopy and has been applied to endoscopy to achieve microscopic observation of gastrointestinal (GI) cells through tissue staining, thus allowing the differentiation of cancerous and noncancerous tissues in real time.To date, ECS observation has been applied to the diagnosis of oesophageal, gastric and colorectal tumours and has shown high sensitivity and specificity.Despite the highly accurate diagnostic capability of this method, the interpretation of the results is highly dependent on the operator's skill level, and it is difficult to train all endoscopists to master all methods quickly. Artificial intelligence (AI)-assisted diagnostic systems have been widely recognized for their high sensitivity and specificity in the diagnosis of GI tumours under general endoscopy. Few studies have explored on ECS for endoscopic tumour identification, and even fewer have explored ECS-based AI in the endoscopic identification of GI tumours, all of which have reached different conclusions. Therefore, we aimed to investigate the value of ECS-based AI in detecting GI tumour to provide evidence for its clinical application.
Style APA, Harvard, Vancouver, ISO itp.
2

Ragunathan, Yoithapprabhunath Thuckanaickenpalayam, Srichinthu Kenniyan Kumar, Deepak Gupta, Diksha Singh, Swetha Pasupuleti i Madhavan Nirmal Ramdas. Effectiveness of Neoadjuvant Molecular-Targeted Chemotherapy in Ameloblastoma - A Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, czerwiec 2022. http://dx.doi.org/10.37766/inplasy2022.6.0018.

Pełny tekst źródła
Streszczenie:
Review question / Objective: The aim of this article is to obtain an in-depth review of ameloblastoma tumor to determine the available level of evidence and the possible benefit of targeted therapeutics for the treatment of BRAF V600E mutation in ameloblastoma tumor. Condition being studied: Ameloblastoma is an epithelium-derived odontogenic tumour that evolved since the prehistoric era. Ameloblastoma is unique among the odontogenic neoplasms occurring in the jaws, because of its locally invasive behaviour and high recurrence rate. Facial asymmetry, displacement of teeth, malocclusion, and pathologic fractures are some of the asymmetrical features that ameloblastoma is known to cause. If left untreated, they often lead to wide tissue destruction and deformity. For the treatment of ameloblastomas, conventional chemotherapy and radiation have been unexplored or contraindicated and to date, wide surgical resection is the only treatment of choice for ameloblastoma tumours, resulting in post-treatment compromised quality of life in the individuals.
Style APA, Harvard, Vancouver, ISO itp.
3

Laguna, Pilar, i Patricia Zondervan. Cryoablation of small kidney tumours. BJUI Knowledge, styczeń 2022. http://dx.doi.org/10.18591/bjuik.0618.v2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Adamczyk, Lukasz, i Jon Oxley. Pathological classification of renal cell tumours. BJUI Knowledge, styczeń 2016. http://dx.doi.org/10.18591/bjuik.0098.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Adamczyk, Lukasz, Paidamwoyo Gwiti i Jon Oxley. Pathological classification of renal cell tumours. BJUI Knowledge, maj 2020. http://dx.doi.org/10.18591/bjuik.0098.v2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Kwan, Amy, i Danish Mazhar. The management of advanced germ cell tumours. BJUI Knowledge, styczeń 2020. http://dx.doi.org/10.18591/bjuik.0659.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Rassweiler, Jens, i Jan Klein. Focal therapy for upper urinary tract tumours. BJUI Knowledge, listopad 2021. http://dx.doi.org/10.18591/bjuik.0124.v2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Adamczyk, Lukasz, i Jon Oxley. Pathological classification of non-RCC renal parenchymal tumours. BJUI Knowledge, styczeń 2016. http://dx.doi.org/10.18591/bjuik.0634.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Adamczyk, Lukasz, Paidamwoyo Gwiti i Jon Oxley. Pathological classification of non-RCC renal parenchymal tumours. BJUI Knowledge, maj 2020. http://dx.doi.org/10.18591/bjuik.0634.v2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Ashkenazi-Kimmel, T. Amplification of oncogenes in early-stage, radiation-induced rat skin tumours. Office of Scientific and Technical Information (OSTI), październik 1989. http://dx.doi.org/10.2172/5566112.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Tumours” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii